Enhancing targeted radiotherapy by copper(II)diacetyl-bis(N 4-methylthiosemicarbazone) using 2-deoxy-D-glucose

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5496-5504

  Aft, Rebecca L ^a,c,d,e   Lewis, Jason S ^b,c   Zhang, Fanjie ^a   Kim, Joonyoung ^b   Welch, Michael J ^b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER DERIVATIVE; COPPER DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE); COPPER PYRUVALDEHYDE BIS(N4 METHYLTHIOSEMICARBAZONE); CYTOTOXIC AGENT; DEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER CELL DESTRUCTION; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG UPTAKE; ENERGY METABOLISM; HYPOXIA; IMAGE ANALYSIS; IONIZING RADIATION; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COPPER RADIOISOTOPES; DEOXYGLUCOSE; DRUG SYNERGISM; FLUORODEOXYGLUCOSE F18; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS; THIOSEMICARBAZONES;

EID: 0141592797     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Brown, M. The hypoxic cell: a target for selective cancer therapy. Eighteenth Bruce F. Cain Memorial Lecture. Cancer Res., 59: 5863-5870, 1999.
2. Ryan, P., and Chabner, B. On receptor inhibitors and chemotherapy. Clin. Cancer Res., 6: 4607-4609, 2000.
3. Coleman, C., and Mitchell, J. Clinical radiosensitization: why it does and does not work. J. Clin. Oncol., 17: 1-3, 1999.
4. Hortobagyi, G., and Budzar, A. Current status of adjuvant chemotherapy for primary breast cancer: progress and controversy. CA Cancer J. Clin., 45: 199-226, 1995.
5. Tannock, I. Treatment of cancer with radiation and drugs. J. Clin. Oncol., 14: 3156-3174, 1996.
6. Warburg, O. On the origin of cancer cells. Science (Wash. DC), 123: 309-314, 1956.
7. Weber, G. Enzymology of cancer cells. N. Engl. J. Med., 296: 541-551, 1977.
8. Kan, O., Baldwin, S., and Whetton, A. Apoptosis is regulated by the rate of glucose transport in an interleukin 3 dependent cell line. J. Exp. Med., 180: 917-923, 1994.
9. Vander Heiden, M., Plas, D., Rathmell, J., Fox, C., Harris, M., and Thompson, C. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol. Cell. Biol., 21: 5899-5912, 2001.
10. Aft, R., Zhang, F., and Gius, D. Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death. Br. J. Cancer, 87: 805-812, 2002.
11. Waki, A., Kato, H., Yano, R., Sadato, N., Yokoyama, A., Ishii, Y., Yonekura, Y., and Fujibayashi, Y. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl. Med. Biol., 25: 593-597, 1998.
12. Younes, M., Lechago, L., Somoano, J., Mosharaf, M., and Lechago, J. Wide distribution of the human erythrocyte glucose transporter Glut 1 in human cancers. Cancer Res., 56: 1164-1167, 1996.
13. Brown, R., and Wahl, R. Over-expression of Glut1 glucose transporter in human breast cancer: an immunohistochemistry study. Cancer (Phila.), 15: 2979-2985, 1993.
14. 18F]2-deoxy-2-fluoro-D-glucose. J. Nucl. Med., 19: 1154-1161, 1978.
15. Arora, K., Parry, D., and Pedersen, P. Hexokinase receptors: preferential enzyme binding in normal cells to non-mitochondrial sites and in transformed cells to mitochondrial sites. J. Bioenerg. Biomembr., 24: 47-53, 1992.
16. Rempel, A., Mathupala, S., Griffin, C., Hawkins, A., and Pedersen, P. Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. Cancer Res., 56: 2468-2471, 1996.
17. Bos, R., van der Hoeven, J., van der Wall, E., van der Groep, P., van Diest, P., Comans, E., Joshi, U., Semenza, G., Lammertsma, A., and Molthoff, C. Biological correlates of 18Fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J. Clin. Oncol., 20: 379-338, 2002.
18. Kern, K., and Norton, J. Inhibition of established rat fibrosarcoma growth by the glucose antagonist 2-deoxy-D-glucose. Surgery, 102: 380-385, 1987.
19. Liu, X., Kim, C., Kurbanov, F., Honzatko, R., and Fromm, H. Dual mechanisms for glucose 6-phosphate inhibition of human brain hexokinase. J. Biol. Chem., 274: 31155-31159, 1999.
20. 3H-2-deoxyglucose in murine tumor models. Nucl. Med. Biol., 23: 533-541, 1996.
21. Liu, X., Gupta, A., Corry, P., and Lee, Y. Hypoglycemia-induced c-Jun phosphorylation is mediated by c-Jun N-terminal kinase 1 and Lyn kinase in drug-resistant human breast carcinoma MCF-7/ADR cells. J. Biol. Chem., 272: 11690-11693, 1997.
22. Spitz, D., Sim, J., Ridnour, L., Galoforo, S., and Lee, Y. Glucose deprivation-induced oxidative stress in human tumor cells: a fundamental defect in metabolism? Ann. NY Acad. Sci., 899: 349-362, 2000.
23. Nomura, K., Imai, H., Koumura, T., Arai, M., and Nakagawa, Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase suppresses apoptosis mediated by a mitochondrial death pathway. J. Biol. Chem., 274: 29294-29302, 1999.
24. Kaplan, O., Lyon, R., Faustino, P., Straka, E., and Cohen, J. Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy of metabolism. Cancer Res., 50: 544-551, 1990.
25. Laszlo, J., Humphreys, S., and Goldin, A. Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors. J. Natl. Cancer Inst., 24: 267-280, 1960.
26. Mohanti, B., Rath, G., Anantha, N., Kannan, V., Das, B., Chandramouli, B., Banerjee, A., Das, S., Jena, A., Ravichandran, R., Shai, U. P., Kumar, R., Kapoor, N., Kalia, V., Dwarkanath, B. S., and Jain, V. Improving cancer radiation therapy with 2-deoxy-D-glucose: Phase I/II clinical trials on human cerebral gliomas. Int. J. Radiat. Oncol. Biol. Physics, 35: 103-111, 1996.
27. Fujibayashi, Y., Taniuchi, H., Yonekura, Y., Ohtani, H., Konishi, J., and Yokoyama, A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med., 38: 1155-1160, 1997.
28. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J. Nucl. Med., 40: 177-183, 1999.
29. 4-methylthiosemicarbazone) as a hypoxic tracer in patients with lung cancer. Ann. Nucl. Med., 14: 323-328, 2000.
30. 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Intl. J. Rad. Onc. Biol. Phys., 55: 1233-1238, 2003.
31. 60Cu-ATSM. Eur. J. Nucl. Med., 30: 844-850, 2003.
32. 4-methylthiosemicarbazone): an agent for radiotherapy. Proc. Natl. Acad. Sci. USA, 98: 1206-1211, 2001.
33. 4-mtheylthiosemicarbazone): effect of changes in tissue oxygenation. J. Nucl. Med., 42: 655-661, 2001.
34. Dearling, J., Lewis, J., Mullen, G., Welch, M., and Blower, P. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur. J. Nucl. Med., 25: 788-792, 1998.
35. Maurer, R., Blower, P., Dilworth, J., Reynolds, C., Zheng, Y., and Mullen, G. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J. Med. Chem., 45: 1420-1431, 2002.
36. 4-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging. Cancer Res., 62: 445-449, 2002.
37. 67Cu. Proc. Natl. Acad. Sci. USA, 93: 6814-6818, 1996.
38. 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor positive tumor-bearing rat model. Clin. Cancer Res., 5: 3608-3616, 1999.
39. Adelstein, S. J. The Auger process: a therapeutic promise? Am. J. Roentgenol., 160: 707-713, 1993.
40. O'Donoghue, J., and Wheldon, T. Targeted radiotherapy using Auger electron emitters. Phys. Med. Biol., 41: 173-1992, 1996.
41. Hockel, M., and Vaupel, P. Tumor hypoxia: definitions and current clinical, biological, and molecular aspects. J. Natl. Cancer Inst., 93: 266-276, 2001.
42. Lin, X., Zhang, F., Bradbury, M., Kaushal, A., Spitz, D., Aft, R., and Gius, D. 2-Deoxy-D-glucose induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res., 63: 2413-2417, 2003.
43. Purohit, S., and Pohlit, W. Experimental evaluation of the glucose anti-metabolite, 2-deoxy-D-glucose as a possible adjuvant to radiotherapy of tumors. I. Kinetics of growth and survival of Ehrlich ascites cells in vitro and of growth of solid tumors after 2-DG and x-irradiation. Int. J. Radiat. Oncol. Biol. Phys., 8: 495-499, 1981.
44. McCarthy, D., Bass, L., Cutler, P., Shefer, R., Klinkowstein, R., Herrero, P., Lewis, J., Cutler, C., Anderson, C., and Welch, M. High purity production and potential applications of copper-60 and copper-61. Nucl. Med. Biol., 26: 351-358, 1999.
45. 64Cu using a biomedical cyclotron. Nucl. Med. Biol., 24: 35-43, 1997.
46. 4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. J. Nucl. Med., 21: 336-341, 1994.
47. Hamacher, K., Coenen, H., and Stocklin, G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]fluoro-2-deoxy-D-glucose using a aminopolyether supported nucleophilic substitution. J. Nucl. Med., 27: 235-238, 1986.
48. Cherry, S., Shao, Y., Silverman, R., Meadors, K., Siegel, S., Chatziioannou, A., Young, J., Jones, W., Moyers, J., Newport, D., Boutenouchet, A., Faquhar, T., Andreaco, M., Paulus, M., Binkley, D., Nutt, R., and Phelps, M. MicroPET: a high resolution PET scanner for imaging small animals. IEEEE Trans. Nucl. Sci., 44: 1161-1166, 1997.
49. Defrise, M., Kinahan, D., Townsend, C., Michel, M., and Newport, D. Exact and approximate rebinning algorithms for 3-D PET data. IEEEE Trans. Med. Imaging, 16: 145-158, 1997.
50. Landau, B., Laszlo, J., Stengle, J., and Burk, D. Certain metabolic and pharmacologic effects in cancer patients given an infusion of 2-deoxy-D-glucose. J. Natl. Cancer Inst., 21: 485-494, 1958.
51. Ball, H., Wick, A., and Sanders, C. Influence of glucose anti-metabolites on the Walker tumor. Cancer Res., 17: 235-239, 1957.
52. Pauwels, E., Strum, E., Bombardieri, E., Cleton, F., and Stokkel, M. Positron-emission tomography with [18F]fluorodeoxyglucose. Part 1. Biochemical uptake mechanism and its implications for clinical studies. J. Cancer Res. Clin. Oncol., 126: 549-559, 2000.
53. Mohanti, B., Rath, G., Anantha, N., Kannan, V., Das, B., Chandramouli, B., Banerjee, A., Das, S., Jena, A., Ravichandran, R., Sahi, U., Kumar, R., Kalia, V., Dwarkanath, B., and Jain, V. Improving cancer radiotherapy with 2-deoxy-D-glucose: Phase I/II trials on cerebral gliomas. Int. J. Radiat. Oncol. Biol. Phys., 35: 103-111, 1996.
54. Shibamoto, Y., Nishimoto, S., Mi, F., Sasai, K., Kagiya, T., and Abe, M. Evaluation of various types of new hypoxic cell sensitizers using the EMT6 single cell-spheroid-solid tumor system. Int. J. Radiat. Biol., 52: 347-357, 1987.
55. Franko, A. Hypoxic fraction and binding of misonidazole in EMT6/Ed multicellular tumor spheroids. Radiat. Res., 103: 89-97, 1985.
56. Moulder, J., and Rockwell, S. Hypoxic fraction of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys., 10: 695-712, 1984.
57. Mesmer, O., Lu, Z., and Lo, T. Effects of 2-deoxy-D-glucose on the functional state of the rat myoblast GLUT 1 transporter. Biochem. Mol. Biol. Int., 40: 217-233, 1996.
58. Herrero, P., Markham, J., Weinheimer, C., Anderson, C., Welch, M., Green, M., and Bergmann, S. Quantification of regional myocardial perfusion with generator-produced 62Cu-PTSM and positron emission tomography. Circulation, 87: 173-183, 1993.
59. 4-methylthiosemicarbazone)copper(II): synthesis and evaluation as a possible emission tomography tracer for cerebral and myocardial perfusion. J. Nucl. Med., 31: 1989-1996, 1990.
60. 4-methylthiosemicarbazone (Cu-PTSM). Ann. Nucl. Med., 13: 287-292, 1999.
61. 4-mtheylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann. Nucl. Med., 15: 499-504, 2001.
62. 67Cu. Int. J. Radiat. Biol., 55: 365-384, 1989.
63. 64Cu atoms incorporated in cells under either in vitro or in vivo conditions. Radiat. Environ. Biophys., 26: 115-123, 1987.
64. Anderson, C., Dehdashti, F., Cutler, P., Schwarz, S., Laforest, R., Bass, L., Lewis, J., and McCarthy, D. Copper-64-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med., 42: 213-221, 2001.
65. Philpott, G., Schwarz, S., Anderson, C., Dehdashti, F., Connett, J., Zinn, K., Meares, C., Cutler, P., Welch, M., and Siegel, B. RadioimmunoPET: detection of colorectal carcinoma with positron emitting copper-64-labeled monoclonal antibody. J. Nucl. Med., 36: 1818-1824, 1995.
66. Pohlit, W., and Harder, D. The shape of dose-survival curves for mammalian cells and repair of potentially lethal damage analyzed by hypertonic treatment. Radiat. Res., 87: 613-634, 1981.
67. Barendsen, G. Differences between biological effects of high LET and low LET radiations in relation to their application in radiotherapy. Radiol. Clin., 46: 380-389, 1977.
68. Ostashevsky, J. prediction of cell survival curves from DNA double-stranded break repair for low and high LET radiation. Int. J. Radiat. Biol., 56: 999-1010, 1989.
69. Clavo, A., Brown, R., and Wahl, R. Fluorodeoxyglucose uptake in human cancer cells is increased by hypoxia. J. Nucl. Med., 36: 1625-1632, 1995.
70. Aloj, L., Caraco, C., Jagoda, E., Eckelman, W., and Neumann, R. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture. Cancer Res., 59: 4709-4714, 1999.
71. Burgman, P., O'Donoghue, J., Humm, J., and Ling, C. Hypoxia-induced increase in FDG uptake in MCF7 cells. J. Nucl. Med., 42: 170-175, 2001.
72. Hamilton, E., Fennell, M., and Stafford, D. Modification of tumor glucose metabolism for therapeutic benefit. Acta Oncol., 34: 429-433, 1995.
73. Lichter, A., and Lawrence, T. Recent advances in radiation oncology. N. Engl. J. Med., 332: 371-379, 1995.
74. Jha, B., and Pohlit, W. Reversibility of inhibition of DNA double strand break repair by 2-deoxy-D-glucose. Int. J. Radiat. Biol., 63: 459-467, 1993.
75. Jain, V., Kalia, V., Sharma, R., Maharajan, V., and Menon, M. Effects of 2-deoxy-D-glucose on glycolysis, proliferation kinetics and radiation response of human cancer cells. Int. J. Radiat. Oncol. Biol. Phys., 11: 943-950, 1985.
76. Gaze, M. The current status of targeted radiotherapy in clinical practice. Phys. Med. Biol., 41: 1895-1903, 1996.